These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33086187)

  • 41. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
    Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
    Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospects for a dengue virus vaccine.
    Whitehead SS; Blaney JE; Durbin AP; Murphy BR
    Nat Rev Microbiol; 2007 Jul; 5(7):518-28. PubMed ID: 17558424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
    Strouts FR; Popper SJ; Partidos CD; Stinchcomb DT; Osorio JE; Relman DA
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004731. PubMed ID: 27214236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
    Coronel D; García-Rivera EJ; Rivera DM; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Wang H; Pagnon A; Jantet-Blaudez F; Peñalosa LAR; Dayan G; Zambrano B; DiazGranados CA; Noriega F
    Pediatr Infect Dis J; 2020 Oct; 39(10):961-968. PubMed ID: 32932330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.
    Wichmann O; Vannice K; Asturias EJ; de Albuquerque Luna EJ; Longini I; Lopez AL; Smith PG; Tissera H; Yoon IK; Hombach J
    Vaccine; 2017 Oct; 35(42):5535-5542. PubMed ID: 28893477
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
    Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
    J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
    Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
    Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dengue vaccine: an update.
    Huang CH; Tsai YT; Wang SF; Wang WH; Chen YH
    Expert Rev Anti Infect Ther; 2021 Dec; 19(12):1495-1502. PubMed ID: 34182875
    [No Abstract]   [Full Text] [Related]  

  • 49. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
    Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of interferences between dengue vaccine serotypes in a monkey model.
    Guy B; Barban V; Mantel N; Aguirre M; Gulia S; Pontvianne J; Jourdier TM; Ramirez L; Gregoire V; Charnay C; Burdin N; Dumas R; Lang J
    Am J Trop Med Hyg; 2009 Feb; 80(2):302-11. PubMed ID: 19190230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis.
    Quinan BR; Versiani AF; da Fonseca FG
    Vaccine; 2016 Dec; 34(50):6120-6122. PubMed ID: 27817963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
    Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
    Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DENGUE VACCINES.
    Thisyakorn U; Thisyakorn C
    Southeast Asian J Trop Med Public Health; 2015; 46 Suppl 1():138-45. PubMed ID: 26506740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
    Lee JS; Lourenço J; Gupta S; Farlow A
    Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.
    Li XF; Deng YQ; Yang HQ; Zhao H; Jiang T; Yu XD; Li SH; Ye Q; Zhu SY; Wang HJ; Zhang Y; Ma J; Yu YX; Liu ZY; Li YH; Qin ED; Shi PY; Qin CF
    J Virol; 2013 Dec; 87(24):13694-705. PubMed ID: 24109223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent Developments in Recombinant Protein-Based Dengue Vaccines.
    Tripathi NK; Shrivastava A
    Front Immunol; 2018; 9():1919. PubMed ID: 30190720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes.
    Khanam S; Rajendra P; Khanna N; Swaminathan S
    BMC Biotechnol; 2007 Feb; 7():10. PubMed ID: 17302980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dengue vaccine development: challenges and prospects.
    Wilder-Smith A
    Curr Opin Infect Dis; 2022 Oct; 35(5):390-396. PubMed ID: 36098260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.